JPMorgan lowered the firm’s price target on Endava (DAVA) to $10 from $13 and keeps a Neutral rating on the shares. The company reported a fiscal Q1 miss and guidance cut, the analyst tells investors in a research note. The firm sees limited share upside until consensus estimates are “de-risked.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAVA:
- Endava price target lowered to $9 from $12 at Needham
- Endava Reports Q1 FY2026 Results with Strategic Partnership Highlight
- Endava price target lowered to $15 from $18 at Guggenheim
- Endava Reports Q1 FY2026 Revenue Decline Amid Challenges
- Endava’s Earnings Call: Strategic Wins Amid Financial Hurdles